Good afternoon. Thank you for attending today's NanoString fourth quarter and fiscal year 2022 operating results call. My name is Porum, and I will be your moderator for today's call. All lines will remain muted during the presentation portion of the call, with an opportunity for questions and answers at the end. If you would like to ask a question, please press star one on your telephone keypad. It is now my pleasure to pass the conference over to our host, Doug Farrell, Investor Relations of NanoString. Mr. Farrell, please proceed. Thank you, operator. Thanks for joining us today. On the call with me today is Brad Gray, our President and CEO, as well as our CFO, Tom Bailey. Earlier today, we released our financial results for the fourth quarter and fiscal year ended December 31st, 2022. During this call, we may make statements that are forward-looking, including statements about financial and operating projections, future business growth, trends and related factors, expectations regarding future operating results, future cash flows, current and future instrument orders, prospects for expanding and penetrating our addressable markets, and our strategic focus and objectives, as well as the development status and anticipated success of recent product offerings, and the impact of macroeconomic factors. Forward-looking statements are subject to risks and uncertainties, including those described in our SEC filings. Our results may differ materially from those projected, and we undertake no obligation to update any forward-looking statements. Later in the call, Tom will be discussing our financial results and guidance for 2023. Be prepared as a supplement to GAAP financial measures, selected non-GAAP adjusted measures, the calculation of which are described in detail in our press release. Throughout this call, all financial measures will be GAAP unless otherwise noted. You can also find reconciliations of GAAP to non-GAAP measures as well as a description, limitations and rationale for using each such measure in this afternoon's press release. To aid analysts and investors in building their models, we have posted exhibits under the "Financial Information" tab of our Investor Relations homepage that include a presentation of our non-GAAP or adjusted measures and selected other financial data. I'd like to remind everyone that we'll be participating in the Cowen Healthcare Conference in Boston next week. In addition to our fireside corporate discussion, Brad will also be participating in a panel focused on AI-based genomics and drug discovery on Tuesday afternoon that will include participants from NVIDIA and Genentech. We look forward to having the opportunity to speak with many of you then. I'd like to turn the call over to Brad. Thanks, Doug. Good afternoon. Thank you for joining us today. We are thrilled with the momentum that's building in the spatial biology market. NanoString currently offers researchers the most compelling portfolio of spatial biology solutions, and we believe that ongoing innovations will continue to extend our lead. As we begin 2023, we enjoy both growing demand and a substantial backlog and believe that we are poised for strong revenue growth. I'll begin by recapping some highlights from our fourth quarter and fiscal year 2022 before outlining our priorities for 2023. 2022 was a year of transition for spatial biology as the arrival of single-cell imagers both expanded demand and shifted mix within the market. With our best-in-class CosMx Spatial Molecular Imager, we were able to capitalize on this trend and grew our total spatial biology instrument orders by 50% year-on-year to approximately 250 systems across CosMx and our GeoMx Digital Spatial Profiler. In the process, we broadened our customer base beyond the core oncology researchers who we've served in the past, reaching discovery researchers who've embraced single-cell biology. This has allowed us to generate about 70% of our CosMx orders from customers who are new to NanoString. Our finish to the year was particularly strong. During Q4, we generated orders for more than 105 spatial instruments and began delivering the first CosMx commercial shipments. At the year-end, we had captured orders for around 180 CosMx instruments and built a revenue backlog valued at approximately $40 million. We also saw tremendous scientific momentum as we surpassed 7,000 peer-reviewed papers enabled by our technologies, including approximately 200 using our spatial biology platforms. CosMx was featured in the December 2022 issue of Nature Biotechnology, with a high-resolution single-cell image of RNA and protein from CosMx gracing the journal's cover. CosMx was also recognized as one of the Top 10 innovations by The Scientist magazine in their annual survey highlighting products that are poised to revolutionize research and advance our scientific understanding. Our spatial biology platforms also reached more mainstream media, as in the January issue of National Geographic, which contained an article on aging which highlighted Alzheimer's research from Wake Forest University Medical Center using both GeoMx and CosMx to perform high-resolution mapping of brain tissue. As we begin 2023, we're convinced that our early mover advantage, the scalability of our technologies, and our product innovation engine put us in a leading position in the spatial biology market. Now I'd like to provide an outline of our strategic objectives for the year ahead. Our first objective for 2023 is to rapidly penetrate the spatial biology market. Spatial biology was Nature's Method of the Year just two years ago, and the field is still in its infancy. We estimate that the addressable market in spatial biology research alone is valued at $6 billion across 7,000 labs, only 5% of which have been penetrated to date. Our focus is on winning share as this market develops by capturing instrument orders and making our customers successful. We kicked off 2023 by providing important updates on our spatial biology product portfolio and roadmap at the Advances in Genome Biology and Technology conference, or AGBT. Spatial biology featured prominently at AGBT this year, representing about 25% of the total presentations and posters. For the second year in a row, NanoString had the most spatial biology studies of any technology provider, almost double the number of spatial abstracts of our nearest competitor. AGBT provides a perfect venue in which to build our brand with basic discovery researchers who are still getting to know NanoString. We capitalized on the opportunity to be the gold sponsor for this year's meeting. I could not be more pleased with our showing. Following the conclusion of the meeting, consulting firm DeciBio published a survey of attendees that rated spatial biology as the most exciting space, with NanoString the most mentioned company. During the meeting, we achieved three key objectives. First, we publicly demonstrated our AtoMx Spatial Informatics Platform. AtoMx is a flexible, open source, cloud-based informatics platform that provides secure, scalable storage and analysis for spatial biology researchers. Think of it as the iCloud of NanoString spatial biology ecosystem. Customer interest in AtoMx is extremely high, and we have conducted dozens of AtoMx demos during the meeting. Feedback from the customers was extremely positive. Those who have already ordered a CosMx system cannot wait to get their hands on the total solution provided by CosMx plus AtoMx. Researchers appreciate that AtoMx allows them to focus on the science and avoid the headaches of building and maintaining their own compute and storage infrastructure. AtoMx also provides this highly scalable storage and compute power for a fraction of the upfront cost of on-site capabilities, making the decision to move data to the cloud an easy one. Second, we used AGBT to unveil our CosMx assay roadmap, which will continue to set the standard for plex. Plex is the term used to describe the number of unique genes or proteins that a platform can analyze. We believe plex is the most critical differentiator in the spatial imager class, as it directly determines the amount of information generated from precious samples. Our belief that plex is the number one attribute is grounded in our real-world experience, as when we have offered customers using our CosMx Technology Access Program the choice between our 1,000 -plex assay or our cheaper and faster turnaround time, 100- plex assay, every single customer opted for the higher -plex assay. The plex provided by CosMx already stands head and shoulders above the competition, with our currently available 1,000- plex assays offering 2x the amount of data per sample as imagers from other manufacturers. As we showed at AGBT, we're pushing plex further and faster than anyone expected. We revealed our 6,000- plex human RNA assay, which provides 12x the data per sample of that provided by competing platforms. To be clear, these data were not from some small-scale proof of concept experiment. We have worked with multiple research customers to use this assay to generate real insights, and two of those customers were on hand at AGBT presenting and discussing their 6,000- plex data. Our 6,000- plex offering is already in full product development, and we plan to make it available through our Technology Access Program in the fourth quarter and to begin shipping it to customers early next year. Finally, we used the AGBT meeting to highlight an exciting new collaboration with Dr. Chris Mason and others at the Weill Cornell Medicine called the Spatial Atlas of Human Anatomy, or SAHA. The abstract described SAHA was selected for a plenary talk during the opening night of AGBT. As Dr. Mason described, researchers at Cornell will use the GeoMx Whole Transcriptome Atlas to analyze tissues from 30 different organs provided by a healthy and genetically diverse population of adults. The researchers plan to make the atlas available to researchers around the world through periodic releases. We believe that SAHA will become an important reference database of normal tissue that which may be crucial for enabling precision medicine therapeutic approaches. Coming out of AGBT, it is clear to us that CosMx has the performance attributes to remain the platform of choice for single-cell imaging. Our confidence in our ability to rapidly penetrate the spatial biology market has never been higher. Our second objective is to deliver more predictable revenue growth over the course of 2023. In 2022, we struggled to predict the mix of spatial biology instrument demand between our CosMx and GeoMx systems, resulting in inconsistent revenue. We believe that 2023 is set up to be a very different year. First, we're shipping and recognizing revenue on both spatial biology instruments, so the overall revenue will be less sensitive to mix. Second, we expect our primary revenue growth driver to be CosMx instrument orders that we've already captured and which are currently in backlog. We plan to execute a metered rollout of CosMx instrument shipments designed to provide excellent customer experience as we scale up manufacturing, installs, and training. We will start with a manageable number of installations during Q1, increasing the pace in Q2, and then remaining at a relatively steady pace over the balance of the year. This gives us a high degree of confidence in the predictability of our revenue growth in 2023. Our third strategic objective is to demonstrate continued progress towards cash breakeven. This is a prime directive for the company, and everyone on our team knows it. During Q4, we made hard choices to optimize our cost structure heading into 2023. We reduced our headcount from about 800 employees to about 700 employees. For 2023, we're guiding revenue growth in the range of 34%-41%, which we are expecting to deliver while modestly lowering our operating expenses, driving a substantial improvement in our adjusted net loss for the year and an improving financial profile quarter by quarter throughout the year. We exited 2022 with more than $195 million of cash and equivalents and believe that with these resources in hand, we are well-positioned to sustain our operations to breakeven and profitable growth. I'd now like to turn the call over to Tom to review the details of our financial results and to provide our financial outlook for the year. Thanks, Brad, thanks, all, for joining us today. For the fourth quarter of 2022, revenue was $34.4 million in the middle of our guidance range. Q4 Spatial Biology revenue was $14.8 million above the upper end of our Spatial revenue guidance range. Our cumulative CosMx SMI order book as of December 31st was approximately 180 systems, including about 80 new orders received in Q4. We shipped the first 13 CosMx systems to customers in Q4, generating revenue of approximately $3 million, leaving us a backlog of over 165 systems we expect to ship in 2023 with a revenue value of approximately $40 million. Q4 GeoMx revenue was $11.4 million, a 23% sequential improvement. GeoMx instrument revenue was $5.4 million, reflecting over 25 new system ships. Consumables revenue was $6 million, and Q4 annualized GeoMx pull-through was about $73,000 per system. At the end of Q4, our GeoMx installed base was approximately 350 instruments, with about 20 instruments installed during the quarter. Q4 nCounter revenue, which includes all of service, was $19.6 million. nCounter instrument revenue was $2.5 million. Consumables revenue was $12.1 million, and Q4 annualized nCounter pull-through was approximately $44,000 per system. At the end of Q4, our nCounter installed base was approximately 1,120 instruments, with about 15 instruments installed during the quarter. Turning to margins and expenses, commentary reflects non-GAAP or adjusted results, which for Q4 exclude the impact of stock-based compensation, depreciation, litigation, and certain non-recurring restructuring and severance expenses. Please refer to our press release as well as the exhibits we have posted to our investor relations webpage for detailed information on how our non-GAAP or adjusted measures are prepared. Q4 adjusted gross margin was 43%. Our Q4 adjusted gross margin was impacted by manufacturing variances held on our balance sheet due mainly to under-absorbed labor we expensed in Q4 together with the reduction in our workforce. Inclusion of these additional charges in Q4 cost of goods sold impacted our Q4 adjusted gross margin by about 8 percentage points. Q4 adjusted R&D expense was $15 million, a decrease of 4% year-over-year, and adjusted SG&A expense was $27.5 million, an increase of 4% year-over-year. Q4 adjusted operating expense trends reflect the initial impact of expense reductions we implemented in Q4, balanced by investments we continue to make in our spatial biology manufacturing capacity and efficiencies and in our spatial biology product development, field support, and commercial initiatives. Our Q4 adjusted EBITDA loss was $27.7 million. We exited the quarter with approximately $196.5 million of cash equivalents, and short-term investments. Transitioning to our 2023 outlook, we expect 2023 revenue of $170 million-$180 million, representing annual growth of 34%-41%. Our range includes Spatial Biology revenue of $95 million-$100 million, a more than doubling of our Spatial revenue as compared to 2022. Our nCounter revenue, which includes all of service and other revenue, is expected to be in the range of $75 million-$80 million, a 6% decline at the midpoint of the range as this more mature part of our business moved into cash cow mode. We expect about 40% of total revenue to be recorded in the first half of 2023 and about 60% in the second half. Seasonality will be strongly influenced by the pace of CosMx shipments, which will steadily increase over the course of the year as we increase our capacity to manufacture and install CosMx instruments. We expect to clear our current order backlog of over 165 units by the fourth quarter. We expect 2023 adjusted EBITDA loss to range from $65 million-$75 million, a significant improvement compared to 2022, more substantively in the second half of the year as our Spatial Biology revenue grows on a reduced operating expense base. We expect adjusted gross margins will be temporarily lower in 2023 as our revenue mix shifts towards CosMx instruments before improving in 2024 and beyond as these systems begin to pull through higher-margin consumables. For the first quarter of 2023, we expect revenue will be in the range of $32 million-$34 million, reflecting typical sequential and seasonal patterns in our measured pacing of CosMx shipments. Our Q1 range includes $15 million-$16 million of Spatial Biology revenue and $17 million-$18 million of nCounter and Service revenue. I'll turn the call back over to Brad for our closing comments. Thanks, Tom. In closing, we feel great about our setup for 2023. Momentum in our Spatial business is building, and we've established CosMx as a market-leading spatial imager. At year-end, we had a backlog of CosMx orders valued approximately $40 million, giving us excellent visibility to our revenue trajectory for the year. For 2023, we expect to generate healthy revenue growth while reducing operating expenses, which will allow us to work in a disciplined fashion towards achieving cash flow breakeven. With that, I'm left to now open the line for your questions. Certainly. If you would like to ask a question, please press star followed by one on your telephone keypad. If for any reason you would like to remove that question, please press star followed by two. Again, to ask a question, press star one. As a reminder, if you are using a speakerphone, please remember to pick up your handset before asking your question. Our first question comes from the line of Dan Brennan with TD Cowen. Dan, your line is now open. Hey, good afternoon. This is Kyle on for Dan. Thanks for taking the questions. I just wanted to start with nCounter really quickly. You know, what's sort of baked into the guide here from a customer trends perspective? I know this isn't really a, you know, a growth driver here, but what are the puts and takes we should sort of think about where, you know, this number could come in maybe higher or lower this year? Hey, this is Brad. I'll start. I'll let Tom build on my answer. As you know, Kyle, nCounter is really a mature business that's moved into a cash cow mode of operations. You know, it's a business that is about 80% consumables and about 20% instrumentation. Our primary focus is on maintaining the high activity levels of our existing installed base. Most of our sales effort focuses on the consumable portion of nCounter. That being said, we have guided down nCounter for the year. We've guided for a total nCounter revenue inclusive of service down being about down about 5%, which really includes instrument and consumables down an aggregate of 10% offset by some growth in Service revenue. We are not looking for this business to be a growth driver in the future, and I would say there's probably limited opportunity for nCounter at this stage to surprise to the upside. That being said, we think our guide is appropriately conservative given the state of the business, and we don't see a lot of downside risk either. Got it. Moving on to cash burn maybe. You know, you're targeting here for adjusted EBITDA this year. How should we think about the cash burn and that, how that trend throughout the year? Given the burn, you know, how do you plan to fund the business, and do you anticipate needing to raise capital, you know, in the next few years here? Yeah. I would say on the cash burn, Kyle, it would be EBITDA plus a few puts and takes on the cash flow statement. I think using the EBITDA guide is a good proxy for the cash burn would be a great place to start, that you would see improvement in that over the back half of the year, in particular as the CosMx shipments ramp over a flat base of operating expenses. On the capital raise point, no, we don't anticipate having being put into a position to have to do a capital raise. As you look out over subsequent years, the growth in our business over what is now an expense base that we feel is dialed in for the spatial biology business that we intend to support, should put us into a position to be able to get to cash flow breakeven on our existing balance sheet resources. We don't anticipate needing to do another raise to fund the growth of the business. Got it. Thank you. Our next question comes from the line of Dan Arias with Stifel. Dan, your line is now open. Hey, guys. Thanks for the questions here. Brad or Tom, on CosMx, you know, as you guys continue to work the order book higher here, can you just talk a little bit about manufacturing capabilities and the levels at which you start to become constrained on production? Relatedly, you know, what do you think the placement and revenue recognition ceiling is for the year, you know, after which we should think about all incremental activity being a 2024 event or an impact in 2024? Hey, Dan, this is Brad. I'll take a first stab and let Tom build on it if he wishes. Yeah, I'd say right now we're operating in a phase where we're scaling up both our ability to manufacture the CosMx instrument, and we're training our field service engineers and field application scientists on how to install, train, and activate sites. We're doing that at a measured pace in the first quarter that's consistent with, you know, Tom's guide. As I said in my prepared remarks, we expect that pace to basically double from Q1 to Q2 and then remain at a reasonably steady pace through the balance of the year. You asked about the ceiling and our overall kind of spatial instrument shipments for the year. I think implicit in our guide is about 280-300 total spatial instrument placements, by which I mean CosMx plus GeoMx. I think we're in a position to handle that as a wide range of different mixes. I don't think we're baking, I wanna be clear that we're not baking GeoMx recovery, into our guide for the year. You know, we can dial up CosMx shipments over the course of the year if needed, if that's the way that the mix of demand continues to trend. Maybe if I could just follow up on that point on GeoMx. It looks like you shipped seven GeoMx instruments during the quarter. Obviously, the order number was higher than that. What's driving the spread between the two? Then, you know, to your point on what you may or may not be assuming for recovery in GeoMx, what is the pull-through assumption that we should work with? I mean, I know you feel good about the CosMx contributions, just trying to understand the consumables contribution that you kind of have baked in for GeoMx this year. Yeah, I think, you know, we're not currently guiding pull-through for 2023. You know, we're guiding total overall Spatial revenue. We won't be giving pull-through commentary. I think you can look at our. We're not, to be clear, we're not building in a recovery beyond the averages that we saw in 2022. On the question of the number of GeoMx instruments that we shipped in Q4, I think you may have underestimated it, Dan. We actually. I'll turn it over to Tom to speak to that question. Yeah, no, yeah. When you look at the parsing of the revenue, Dan, for Q4, we shipped about 25 GeoMx instruments, and we installed about 20. Remember, there's always a difference between what we ship in rev rec and what we install during the quarter. The number to think about in terms of shipments was about 25 units during the quarter for GeoMx. Okay. Which was an improvement over— Okay. Q4 sequentially by about 25%. Do you think that that spread between installs and shipments stays the same over the course of the year? It varies from quarter to quarter, Dan, depending upon, you know, what our backlog of installs is at the end of the quarter and when the orders tend to come in during the quarter. If you have a more back-end-loaded quarter, sometimes we can have more orders than installs in a given quarter. That's a Q4 phenomenon often, is when that happens. Then we'd have a catch-up in Q1. That's why we typically talk about both those numbers separately, what we've shipped in rev rec versus installed. Keep an eye out for those in our scripts, and if you have questions on those as we go through the modeling, we can address those. Okay. They won't always be the same. All right. I'll hop out. Every quarter. Appreciate it. Thank you. Our next question comes from the line of Kyle Mikson with Canaccord. Kyle, your line is now open. Hey, guys. Thanks for the questions. Congrats on the end of the year. Good seeing you a few weeks ago. Just maybe like a multi-part question on the kind of the financials here going forward. Tom, earlier in the questions you were talking about, like, the cadence of, I think, cash burn and EBITDA. Could you actually just walk through, like, what maybe first half, second half could look like with the EBITDA? I think it was, like, $55 million-$75 million loss for the year. Secondly, with the, you know, you got this $230 million convert coming up in 2025. Clearly that's above, like, you know, that's more than the current cash balance. How are you thinking about that kind of like, you know, timing for that? Like, you know, just overall. Could you think of, you know, Brad, you mentioned nCounter being a cash cow. I mean, what about maybe, like, monetizing that business to offset that, you know, convert over there? Thanks. Yeah. I'll start with the pacing of EBITDA, Kyle. I think the simple way to think about that is we talked about 40% of revenue in the first half and 60% in the second half. If you think about that over kind of, you know, a 50%-ish gross margin and down operating expenses year-over-year, that won't vary a lot from quarter to quarter. That would get you a pretty good proxy of what the pattern for EBITDA improvement would look like over the course of the year. Put simply, expect to see most of the improvement in the second half as compared to the first half. On the convert, you know, I would say with respect to our convertible debt, our 2023 business trajectory here, with the growth that we're seeing sets us up really nicely, with respect to addressing the convert, in particular with the doubling of our spatial business driving really strong revenue growth and we're lower OpEx in 2022. As a result of that setup, we've got a really broad menu of potential options available for addressing the convert and for financing our business in general. We've also still got two years to go before maturity. We'll have a thoughtful urgency. We'll have the opportunity for our business to mature and deliver great results, heading into any need to address the convert. I'll let Brad take the— Yeah. Hi, Kyle. I'll take the question about kind of nCounter's place within NanoString's strategy. You're right. you know, nCounter is a cash cow business. It's no longer the growth driver that it used to be. It still does have tremendous strategic value to the company. you know, it's an amazing brand. you know, it is the platform that has been historically synonymous with NanoString, and it has a huge install base and a set of customer relationships that go with that install base. It also provides while it doesn't provide growth, it provides tremendous cash flow, you know, with revenue on a relatively low amount of sales effort that allows us to reinvest in our rapidly growing spatial business, and we'd be loathe to give that up. You know, that being said, if the right kind of structure came along that or someone was willing to pay real strategic value to that portion of the business, we of course would entertain it as we always would any kind of opportunity that was favorable to our shareholders. Okay. That was great, guys. Thanks so much. Yeah, just sticking with spatial, many of the GeoMx customers, I guess there's like 350 units out there. I don't know how many customers have this, but most of those guys are probably thinking about purchasing one of these single- cell spatial imagers. A lot of those customers are going to CosMx, obviously buying those, and there's a lot of bundles, as you said in the past. How is that trending lately? You know, are there more GeoMx customers skipping CosMx altogether, kind of transitioning to competing imagers? Like, what are you doing to incentivize those customers and entities to kind of stick with NanoString other than just giving away free instruments or other promotions? Yeah, it's a great question, Kyle. You know, the synergy between our two systems is incredibly strong. We think that we've created a product portfolio that's designed to really deliver that synergy to our customers. We really think about three platforms, right? We have GeoMx, which is our whole transcriptome high-throughput system that really allows researchers to ask questions about how samples compare to each other across multicellular regions. We have our CosMx, which is lower throughput, but sort of a deeper studying of a small set of samples, the highest -plex single-cell imager. To tie all those together, we have our AtoMx Spatial Informatics Platform, which allows people to put their data and studies in the same repository and use a familiar set of interfaces to query and get the most out of those datasets. We really do encourage people to sort of purchase whichever of the two instruments is most fitting with their most urgent science. We believe that to the extent that they grow their capabilities, they'll be inclined to purchase another NanoString platform in the future. I mean, I think our early experience with CosMx suggests that's working. You know, 45% of all of our CosMx orders have gone to laboratories that also had GeoMx. Probably 30% of that 45 is the previous GeoMx owners and 15%, the other 15% of the 45, are new to NanoString customers who bought a bundle of both systems at the same time. You know, to incentivize those bundles, we absolutely give price breaks as we would to any large meaningful customer. They're modest and don't impact our revenue. We treat them as really positive things. In terms of how it's been trending, though, you know, over the course of 2022, CosMx went from being an imager that we were selling predominantly to researchers who already knew NanoString through the ownership of a GeoMx, to a system that was predominantly reaching new to NanoString customers who were coming from single- cell biology or other types of science that we have not participated in yet. I would expect the fraction of CosMx going into GeoMx labs to continue to go down as it becomes the first spatial system that many customers choose to adopt. That's okay. That doesn't undermine in any way, the synergy between our systems. We will hope in due course to come back and sell the GeoMx systems to those who first bought CosMx and then later want whole transcriptome profile. Okay. Makes sense. Let me just ask one quick one before I jump. There's been over 100 customer projects delivered using CosMx. I think a lot of those were the TAP program. Any takeaways with respect to those sort of projects, like the reproducibility of the platform in, out in the field, like currently you have these 13 units out there. Anything kinda tangible so far? I think we've had great learnings from both the TAP and the first 13 systems. I'll speak to the TAP first. You know, one of the learnings of TAP is, you know, the huge preference for high- plex that I mentioned in my prepared remarks. We had initially launched TAP with two offerings, a 1,000- plex offering and a 100 -plex offering. Not a single researcher has opted for the 100- plex RNA offering. It strongly validates that our strategy of making plex the most important spec that we continue to be market leaders in. I'd say the other really big learning from the TAP program has been, you know, the very broad tissue compatibility of CosMx. At last count, 68 different types of tissue and tumors, had been studied using CosMx and it just is shown to be a tremendously generalizable instrument. You know, switching gears towards, you know, that first 13 instruments that we shipped in the Q4, we are getting great feedback and success with those first customers. Just in terms of the mix of those customers, yeah, most of them were oncology-oriented researchers. Their geographic spread was similar to our overall business. They spanned, you know, North America, Europe, as well as Asia. They were about 50% new systems, 50% new to NanoString customers, 50% incumbent customers, and a good mix of academic and pharma. They're nicely representative. I think the feedback has been, you know, on the CosMx instrument, people love the ease of use. Even relative to those people who own GeoMx, they find CosMx easier to use and easier to get trained on. There's been great feedback on the quality of the data and the consistency of the results across runs and samples. We've also started to get really positive feedback from them on AtoMx. They love that it's comprehensive and flexible. They're enjoying, initially using the data analysis modules that we have built into the AtoMx system, but they're also beginning to load their own data analysis modules through the open source functionality that we've built in. These groups have experiments lined up. They're sort of moving beyond the training phase and into their own science and experimentation. You know, I'm optimistic that utilization on CosMx will ramp even faster than we saw on GeoMx. Because it's an easier system to use and some of the experimental designs are more obvious. Okay. All really good takeaways. That's great. Thanks, Brad. Thanks, guys. Thank you, Kyle. Our next question comes from the line of Marta Nazarovets from JPMorgan. Marta, your line is now open. Hello. Thanks for taking the question. I just wanted to dig into first quarter a little bit more. You know, you discussed the revenue expectations. Could you perhaps provide a little bit more color on the instrument placements, the EBITDA and cash foreign expectations? Yeah, for the quarter, although that historically have only just guided for revenue, that's the guide that we gave was consistent with that. On the revenue details, we've elected to simplify our approach this year and just guide for Spatial revenue. All the rest of the components of the guidance are consistent with the commentary that we made around, you know, nCounter being managed more on a cash cow basis coming out of the fourth quarter. The measured pacing of CosMx instruments really being the most material impactful thing to the spatial guide in the first quarter relative to the total overall for the year. I think one more thing to add on that is from an EBITDA pacing perspective, I think in Tom's earlier remarks, he made it clear EBITDA will improve sequentially as the year goes on. You know, Q1 will be our lowest EBITDA quarter, meaning the largest loss. As our business grows with more and more CosMx shipments over the course of the year, we'll see that sequentially improving financial profile. Thank you. Our next question comes from the line of John Sourbeer with UBS. John, your line is now open. Hi. Thanks for taking the questions. you know, maybe just start off, any updates on China and how that formed the quarter, and just how do you expect that to recover throughout the year? Yeah. China obviously had a lackluster year overall during the lockdowns last year. You know, we started to see some recovery in the fourth quarter, and we are optimistic that we'll see continued recovery throughout 2023. You know, NanoString built a really fabulous direct sales team in China just as the lockdowns were about to happen. We actually met that team in person for the first time at a global commercial meeting earlier this month. They are, I can say, very impressive and very energized to get out. You know, all that being said, you know, China remains a relatively small part of NanoString's overall revenue profile, maybe between 5% and 10% historically. I hope it'll grow over time, but, you know, we're not counting on a recovery in China as a major growth driver for the company. Got it. I know you're not providing pull-through guidance, but any color just now that you have the instruments out there on the CosMx, just how we think from a high level of how you see that pull-through ramping there to get towards that targeted $70,000-$75,000 annualized range? Yeah. I think it's early days. I don't think we've learned enough to know whether our previous estimates of $75,000 annualized pull through on CosMx are the right ones or not. There's no update there. I guess what I will say is, you know, we've talked publicly about the long learning cycles that we experience in GeoMx, which requires customers to define regions of interest and learn a certain amount of morphology to be able to process their samples quickly and efficiently. You know, it's clear from the early training of CosMx that by skipping that step and allowing researchers to scan the entirety of a slide, the learning curve is a lot faster. My hope is that we will not have the multiyear cycle that GeoMx has required in some cases to get instruments to full utilization, but we'll be looking at a few quarters instead. Stay tuned. We'll be able to say more about that as the year goes on. Got it. Then last one here on my end, and appreciate the guidance around nCounter and that 6% revenue decline. Just any way to think about, you know, the long-term prospect of this business. You know, do you expect similar declines, you know, year-over-year or the long term, or how should we think about this over the next couple years? Yeah, John, I do think we have probably seen peak nCounter revenue. You know, the installed base includes instruments that are now some of them 15 years old. They are not being as actively used as they once were. As the installed base ages, it's likely that pull-through across the entirety of that installed base, exclusive of the inactivated systems, will continue to come down. It's consistent with what our guide is in 2023, and I think if you're building a multiyear model, yeah, look for a long, slow, sort of sunset for nCounter. You know, more, much more than offset by, you know, strong growth on the spatial side. Thanks for taking the questions and, congrats on the quarter. Thank you. Thanks, John. Our next question comes from the line of Tejas Savant with Morgan Stanley. Tejas, your line is now open. Hi guys, this is Edmund on for Tejas. Thank you for taking my questions. Just in terms of the pricing assumptions baked into the guidance for 2023, given all the talk on bundling and discounts for larger customers and your emphasis on capturing the lifetime value of customers versus upfront instrument revenues, how should we be thinking about the pricing assumptions baked into CosMx prices for 2023? Sure. Edmund, I'll take that one. We've assumed modestly lower ASPs on instruments throughout our guide in 2023. Like consistent with the rest of the guidance approach, we've taken a conservative approach to that. It's not materially lower because CosMx does have a higher list price and has a higher ASP than GeoMx does currently, consistent with the other imaging products that are out there, given the specs that we have and features that we feel that's appropriate. I think that if you wanted to keep it simple across all spatial instruments, I think you could just assume that ASPs would be consistent overall when you're looking at the mix of all the different systems with what we realized in 2022, kind of that $230,000-$240,000 per box, would be a good assumption to use for spatial. Got it. That's super helpful. Just on the note of conservatism, if we simply add the CosMx backlog of about $40 million to your 2022 revenues of $127 million, that gets you to $167, which is actually pretty close to the midpoint of your guide. Are you just baking a lot of conservatism in here, or do you genuinely see potential headwinds that could materialize on either the nCounter business or the GeoMx business based on the way you're framing your 2023 outlook? I think one of our key goals this year, Edmund, is to avoid negative surprises. Our guidance is consistent with that approach and with the commentary that we offered at the JPMorgan conference and earlier this year on what folks should expect. I think that was the approach that we used this year and that, I think we feel good about where our range is set currently in the setup heading into this year, both on the top line and on the bottom line with the improvement that we put into expenses coming into this year. Got it. Super helpful, Tom. Then Brad, maybe just one for you. Could you provide some more color on your cell segmentation approach in CosMx? How important are these features to your customers when it comes into comparing you versus your peers? Is that a point of differentiation for you guys, or is it more or less similar across the board? I think based on some of my conversations with researchers in spatial biology, a lot of them have noted that cell segmentation methodologies today are still suboptimal. I was just wondering what you had in the development pipeline for improving this. Thank you. Thank you, Edmund. That's an impressively technical and astute question. Our cell segmentation approach is different from that used by competing imagers. You know, we have a focus on using the protein morphology markers that have been a big part of both the GeoMx and the CosMx rollout to identify the actual cell boundaries and to create a more accurate assignment of RNAs to cells than would be otherwise possible. That's enabled by, you know, an AI machine learning algorithm that identifies cell boundaries and executes segmentation. I think right now we're market leading in that feature, though I'm sure competitors are working quickly to catch up. Cell segmentation is an ongoing area of innovation. Different tissue types have different challenges on cell segmentation. Brain tissue, for instance, is very challenging. It's very morphologically similar and homogeneous despite the fact that, you know, neurons are very different in nature. We are continuing to innovate on cell segmentation algorithms to continue to serve a broader and broader audience of researchers. I think we're market leading at this point in time. Great. Appreciate the details, Brad. Thank you very much for the time today, guys. Thanks, Edmund. This concludes our question and answer session for today's call. I will now pass back to Doug for any final remarks. Thank you. Thanks everybody for joining us today. If you did miss any portion of the call, a replay should be posted in the next couple of hours. Toll- free access to that is 866-813-9403. For international callers, please use 929-458-6194. The conference ID is 176735. With that, this concludes our call. Thank you. Goodbye. This concludes today's call. Thank you for your participation. You may now disconnect your line.